Publicações científicas

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Perez-Fidalgo JA (1,1), Iglesias M (2,2), Bohn U (3,3), Calvo E (4,4), Garcia Y (5,5), Guerra E (6,6), Manso L (7,7), Santaballa A (8,8), Gonzalez-Martin A (9,9).

(1) Department of Medical Oncology, Hospital Clinico Universitario de Valencia, CIBERONC, Spain.
(2) Department of Medical Oncology, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain.
(3) Department of Medical Oncology, Hospital Universitario Dr Negrin, Las Palmas de Gran Canaria, Spain.
(4) Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
(5) Department of Medical Oncology, Hospital Universitario Parc Tauli, Sabadell, Spain.
(6) Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
(7) Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
(8) Department of Medical Oncology, Hospital Politecnico y Universitario La Fe, Valencia, Spain.
(9) Department of Medical Oncology, Clinica Universitaria de Navarra, Madrid, Spain.

Revisão:Future Science OA

Data: 10/Jan/2019

Oncologia Médica

RESUMO

Response to polyadenosine diphosphate ribose polymerase (PARP) inhibitors in platinum-resistant ovarian cancer and in the absence of BRCA mutations is very low.

Combining PARP inhibitors with other agents might overcome this lack of activity. Here we describe the rationale and design of GEICO1601-ROLANDO (resistant ovarian cancer treated with olaparib and pegylated liposomal doxorubin; NCT03161132). ROLANDO is a Phase II single-arm multicenter trial in which patients are treated with a combination of olaparib and pegylated liposomal doxorubicin (PLD) in platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancer regardless of the BRCA mutation status.

The primary end point is progression-free survival at 6 months. Other secondary end points are response rate, disease control rate, quality of life and overall survival.

CITAÇÃO DO ARTIGO  Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra